Spencer Phillips Hey
Spencer Phillips Hey
Harvard Medical School
Verified email at hms.harvard.edu
Title
Cited by
Cited by
Year
Are outcome-adaptive allocation trials ethical?
SP Hey, J Kimmelman
Clinical Trials 12 (2), 102-106, 2015
682015
The questionable use of unequal allocation in confirmatory trials
SP Hey, J Kimmelman
Neurology 82 (1), 77-79, 2014
402014
Benefit, risk, and outcomes in drug development: a systematic review of sunitinib
B Carlisle, N Demko, G Freeman, A Hakala, N MacKinnon, T Ramsay, ...
JNCI: Journal of the National Cancer Institute 108 (1), 2016
382016
A systematic review of trial-level meta-analyses measuring the strength of association between surrogate end-points and overall survival in oncology
A Haslam, SP Hey, J Gill, V Prasad
European Journal of Cancer 106, 196-211, 2019
332019
Assessment of the clinical benefit of cancer drugs receiving accelerated approval
B Gyawali, SP Hey, AS Kesselheim
JAMA internal medicine 179 (7), 906-913, 2019
302019
Countering imprecision in precision medicine
SP Hey, AS Kesselheim
Science 353 (6298), 448-449, 2016
252016
The Risk-escalation Model: A Principled Design Strategy for Early-phase Trials
SP Hey, J Kimmelman
Kennedy Institute of Ethics Journal 24 (2), 121, 2014
182014
Accumulating Evidence and Research Organization (AERO) model: a new tool for representing, analyzing, and planning a translational research program
SP Hey, CM Heilig, C Weijer
Trials 14 (1), 159, 2013
152013
A comparison of response patterns for progression-free survival and overall survival following treatment for cancer with pd-1 inhibitors: a meta-analysis of correlation and …
B Gyawali, SP Hey, AS Kesselheim
JAMA network open 1 (2), e180416-e180416, 2018
142018
Heuristics and Meta-heuristics in Scientific Judgement
SP Hey
The British Journal for the Philosophy of Science 67 (2), 471-495, 2014
132014
The Question of Clinical Equipoise and Patients’ Best Interests
SP Hey, RD Truog
AMA Journal of Ethics 17 (12), 1108-1115, 2015
122015
The FDA, Juno Therapeutics, and the ethical imperative of transparency
SP Hey, AS Kesselheim
Bmj 354, i4435, 2016
102016
Assay sensitivity and the epistemic contexts of clinical trials
SP Hey, C Weijer
Perspectives in Biology and Medicine 56 (1), 1-17, 2013
102013
Is the concept of clinical equipoise still relevant to research?
SP Hey, AJ London, C Weijer, A Rid, F Miller
Bmj 359, 2017
92017
Robust and discordant evidence: Methodological lessons from clinical research
SP Hey
Philosophy of Science 82 (1), 55-75, 2015
92015
Reprioritizing Research Activity for the Post‐Antibiotic Era: Ethical, Legal, and Social Considerations
SP Hey, AS Kesselheim
Hastings Center Report 47 (2), 16-20, 2017
82017
Success, failure, and transparency in biomarker-based drug development: a case study of cholesteryl ester transfer protein inhibitors
SP Hey, JM Franklin, J Avorn, AS Kesselheim
Circulation: Cardiovascular Quality and Outcomes 10 (6), e003121, 2017
72017
What Theories Are Tested in Clinical Trials?
SP Hey
Philosophy of Science 82 (5), 1318-1329, 2015
7*2015
Cell and gene therapy trials: are we facing an ‘evidence crisis’?
M Abou-El-Enein, SP Hey
EClinicalMedicine 7, 13-14, 2019
62019
The Challenges of Validating in Precision Medicine: The Case of Excision Repair Cross‐Complement Group 1 Diagnostic Testing
B Barsanti‐Innes, SP Hey, J Kimmelman
The oncologist 22 (1), 89, 2017
62017
The system can't perform the operation now. Try again later.
Articles 1–20